FDA Expands Pemetrexed Approval for Frontline Pembrolizumab/Chemo Combo in NSCLC

January 31, 2019 – The FDA has expanded the indication for pemetrexed injection in combination with pembrolizumab and platinum-based chemotherapy for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) without EGFR or ALK alterations. The updated indication is based on data from the phase III KEYNOTE-189 trial, which was the basis for the FDA’s full approval of frontline pembrolizumab for use in … (leggi tutto)